HBM Healthcare Investments

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Sphingotec GmbH is a biotechnology company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating in vitro diagnostic solutions that utilize proprietary blood-based protein biomarkers. In addition to its diagnostic offerings, the company develops microtiter plates, which are essential tools in analytical research and diagnostic testing laboratories. By addressing diagnostically underserved critical care conditions, Sphingotec aims to improve patient outcomes through enhanced diagnostic capabilities.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in the United States that specializes in developing innovative cell and gene immunotherapies for the treatment of cancer and autoimmune diseases. The company focuses on chimeric antigen receptor therapies to address multiple myeloma and other forms of cancer. Cartesian Therapeutics employs its proprietary ImmTOR immune tolerance platform, which aims to foster antigen-specific immunity while reducing unwanted immune responses. This approach utilizes a manufacturing platform to introduce mRNA molecules into cells, enhancing their functionality without the risk of integration into the cell's genetic material, as mRNA naturally degrades over time.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

ValCare, Inc. is a medical device company founded in 2012 and located in Irvine, California. The company specializes in designing and developing innovative devices and accessories for the minimally invasive treatment of heart valve disease, particularly focusing on mitral and tricuspid regurgitation. ValCare's transcatheter technology functions as a docking station for replacement prostheses and as a tool for mitral annulus repair, facilitating advanced treatment options for patients with heart disorders. This approach aims to enhance recovery times and improve patient outcomes in the management of heart valve conditions.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Sphingotec GmbH is a biotechnology company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating in vitro diagnostic solutions that utilize proprietary blood-based protein biomarkers. In addition to its diagnostic offerings, the company develops microtiter plates, which are essential tools in analytical research and diagnostic testing laboratories. By addressing diagnostically underserved critical care conditions, Sphingotec aims to improve patient outcomes through enhanced diagnostic capabilities.

Vascular Dynamics, Inc. is a privately-held medical technology company founded in 2008 and based in Irvine, California. The company specializes in developing catheter-delivered implants for the treatment of drug-resistant hypertension. Its primary product, MobiusHD, utilizes a minimally invasive procedure to enhance the body's natural baroreceptor response in the carotid sinus, promoting vasodilation, lowering heart rate, modulating kidney response, and ultimately reducing blood pressure. Vascular Dynamics aims to provide effective treatment options for patients at risk of severe health conditions associated with high blood pressure, such as heart disease, stroke, and kidney disease. The team at Vascular Dynamics has over 75 years of combined experience in medical device development and commercialization.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vascular Dynamics, Inc. is a privately-held medical technology company founded in 2008 and based in Irvine, California. The company specializes in developing catheter-delivered implants for the treatment of drug-resistant hypertension. Its primary product, MobiusHD, utilizes a minimally invasive procedure to enhance the body's natural baroreceptor response in the carotid sinus, promoting vasodilation, lowering heart rate, modulating kidney response, and ultimately reducing blood pressure. Vascular Dynamics aims to provide effective treatment options for patients at risk of severe health conditions associated with high blood pressure, such as heart disease, stroke, and kidney disease. The team at Vascular Dynamics has over 75 years of combined experience in medical device development and commercialization.

Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.

Sphingotec GmbH is a biotechnology company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating in vitro diagnostic solutions that utilize proprietary blood-based protein biomarkers. In addition to its diagnostic offerings, the company develops microtiter plates, which are essential tools in analytical research and diagnostic testing laboratories. By addressing diagnostically underserved critical care conditions, Sphingotec aims to improve patient outcomes through enhanced diagnostic capabilities.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

1000Farmacie is a prominent pharmacy marketplace in Italy that operates an online shopping platform dedicated to providing a diverse selection of pharmaceutical products. By collaborating with a network of independent pharmacies, the company ensures that customers can purchase healthcare items at competitive prices. The platform offers the convenience of same-day delivery to specified locations, enabling users to save both time and money while accessing essential health products.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

ConnectRN, Inc. operates an online platform that connects healthcare providers, such as hospitals and clinics, with qualified nurses seeking employment. Founded in 2014 and based in Newton, Massachusetts, the platform streamlines communication between nurse managers and nursing staff through a web dashboard and an alert system that notifies nurses of available shifts on their mobile devices. This tech-enabled network not only facilitates the filling of open positions in healthcare facilities but also fosters a supportive community for nurses, enhancing their access to job opportunities and professional support.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company focused on the research, discovery, and development of drugs for central nervous system disorders. Founded in 2011 and headquartered in Seongnam, the company is advancing several clinical candidates, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome. Additionally, Relenopride is in Phase 2 trials for a rare neurological disease, while SKL13865, SKL20540, SKL-PSY, and SKL24741 are in various early-phase trials for conditions such as attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to become a leading specialty pharmaceutical company by developing innovative therapies for CNS and metabolic disorders, alongside providing specialized pharmaceutical manufacturing services.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

Ignis Therapeutics is a life science company focused on developing innovative therapies for central nervous system (CNS) conditions. The company aims to transform the treatment paradigm by advancing new therapeutic options that significantly enhance patient outcomes. Ignis Therapeutics is committed to improving the lives of patients by providing additional choices for physicians, thereby addressing unmet medical needs in the CNS field.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases. Using modern machine learning techniques, Odyssey is transforming the landscape of autoimmune treatments. Odyssey Therapeutics was founded in 2018 and is based in San Francisco, California.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Sphingotec GmbH is a biotechnology company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating in vitro diagnostic solutions that utilize proprietary blood-based protein biomarkers. In addition to its diagnostic offerings, the company develops microtiter plates, which are essential tools in analytical research and diagnostic testing laboratories. By addressing diagnostically underserved critical care conditions, Sphingotec aims to improve patient outcomes through enhanced diagnostic capabilities.

ConnectRN, Inc. operates an online platform that connects healthcare providers, such as hospitals and clinics, with qualified nurses seeking employment. Founded in 2014 and based in Newton, Massachusetts, the platform streamlines communication between nurse managers and nursing staff through a web dashboard and an alert system that notifies nurses of available shifts on their mobile devices. This tech-enabled network not only facilitates the filling of open positions in healthcare facilities but also fosters a supportive community for nurses, enhancing their access to job opportunities and professional support.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

ValCare, Inc. is a medical device company founded in 2012 and located in Irvine, California. The company specializes in designing and developing innovative devices and accessories for the minimally invasive treatment of heart valve disease, particularly focusing on mitral and tricuspid regurgitation. ValCare's transcatheter technology functions as a docking station for replacement prostheses and as a tool for mitral annulus repair, facilitating advanced treatment options for patients with heart disorders. This approach aims to enhance recovery times and improve patient outcomes in the management of heart valve conditions.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Visen Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for endocrine diseases. The company is dedicated to addressing significant unmet medical needs in this field, particularly within the Chinese market, and aims to provide both first-in-class and best-in-class treatment solutions for patients of all ages, including those with rare endocrine conditions. With a commitment to patient-centric care, Visen strives to improve treatment outcomes and quality of life for individuals affected by these diseases. The company is backed by a team of experienced professionals with extensive backgrounds in the pharmaceutical industry and operates offices in major Chinese cities such as Shanghai, Beijing, Hong Kong, and Taipei. To further enhance its research, development, and manufacturing capabilities, Visen has established a Greater China research and development site in Suzhou, aiming to deliver advanced treatment options to Chinese patients more effectively.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics that enhance the body’s immune response to cancer. Founded in 2017, the company utilizes its proprietary PREDATOR platform to engineer conditionally activated molecules, known as INDUKINE molecules. These therapeutics are designed to remain inactive in peripheral tissues but activate selectively within the tumor microenvironment, addressing the limitations of traditional proinflammatory immune therapies. By stimulating both adaptive and innate immunity, Werewolf Therapeutics aims to improve cancer treatment outcomes.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Instil Bio is a clinical-stage biotechnology company based in Dallas, Texas, focused on developing and commercializing tumor infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors. The company specializes in utilizing a patient's own T cells, which are harvested from their tumor, expanded, and reinfused to target and eliminate cancer cells. Instil Bio is advancing its proprietary manufacturing technology and has initiated clinical trials, including a planned registrational study for its TIL candidate. Additionally, the company is developing a novel class of genetically engineered TIL therapies through its Co-Stimulatory Antigen Receptor (CoStAR) platform. One of its key pipeline products, ITIL-306, is designed to target FRα, a tumor-associated antigen present in various solid tumors such as ovarian cancer, uterine cancer, non-small cell lung cancer, and renal cancer.

Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Everlife Asia is a buy-and-build platform focused on delivering comprehensive solutions to the healthcare and research sectors. The company operates a group of companies that invest in manufacturers and distributors across Asia, targeting key segments such as in-vitro diagnostics, medical diagnostics, critical care equipment, implants, and consumables. This strategic approach allows Everlife Asia to facilitate access to the fragmented markets within the region, enhancing the efficiency and effectiveness of healthcare delivery.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for neurological diseases. The company's proprietary pipeline includes several product candidates, notably LP352, a next-generation 5-HT2C agonist intended for treating developmental and epileptic encephalopathies. Additionally, Longboard is evaluating LP143, a full agonist of the cannabinoid type 2 receptor, which targets conditions such as amyotrophic lateral sclerosis and Parkinson's disease, as well as LP659, a selective modulator for multiple central nervous system neuroinflammatory disorders. Longboard Pharmaceuticals aims to optimize pharmacology and pharmacokinetics across its drug candidates, enhancing therapeutic outcomes for patients with rare neurological conditions. The company was incorporated in 2020 and was previously known as Arena Neuroscience, Inc.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

BioShin Limited is a clinical-stage biopharmaceutical company based in Pudong, China, focused on developing innovative medicines and therapies for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018, it operates as a wholly owned subsidiary of Biohaven Pharmaceuticals. The company specializes in late-stage product candidates and utilizes clinical trial platforms to explore treatments such as calcitonin gene-related peptide (CGRP) receptor antagonism for migraine and pain, glutamate modulation for Alzheimer’s disease and anxiety disorder, and myeloperoxidase (MPO) inhibition for inflammation and neurodegeneration. BioShin aims to address unmet medical needs in the neurological field, particularly within the Asia-Pacific market.

Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Polyneuron Pharmaceuticals AG is a biotechnology company based in Basel, Switzerland, founded in 2014. The company focuses on developing innovative therapeutics for antibody-mediated autoimmune disorders, particularly those affecting the peripheral nervous system. Its lead candidates include PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron employs a unique platform technology called Antibody-Catch, which utilizes biodegradable glycopolymers to selectively target and eliminate pathogenic autoantibodies while preserving the overall integrity of the immune system. This approach aims to provide safe and effective treatment options for patients suffering from these complex immune disorders.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Sphingotec GmbH is a biotechnology company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating in vitro diagnostic solutions that utilize proprietary blood-based protein biomarkers. In addition to its diagnostic offerings, the company develops microtiter plates, which are essential tools in analytical research and diagnostic testing laboratories. By addressing diagnostically underserved critical care conditions, Sphingotec aims to improve patient outcomes through enhanced diagnostic capabilities.

Sublimity Therapeutics is a specialty pharmaceutical company focused on developing innovative therapies for gastrointestinal and immunological diseases. Headquartered in Dublin, Ireland, with an additional office in Solana Beach, California, the company aims to address unmet clinical needs through its proprietary oral drug delivery technology. This technology enhances the bioavailability of difficult-to-formulate drugs, allowing for effective systemic or localized delivery within the gastrointestinal tract. Sublimity Therapeutics' product portfolio includes treatments for conditions such as ulcerative colitis, Crohn’s disease, graft versus host disease, and transplant rejection, as well as SmPill formulations for various gastrointestinal disorders. The company's lead product is STI-0529, specifically designed for moderate to severe ulcerative colitis. Founded in 2000 and formerly known as Sigmoid Pharma, Sublimity Therapeutics is committed to advancing oral pharmaceutical formulation technologies to improve patient outcomes in its targeted therapeutic areas.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Everest Medicines Limited is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017. The company focuses on licensing, developing, and commercializing innovative therapies to meet critical unmet medical needs in Greater China and other Asia Pacific markets. Its diverse portfolio includes eight clinical-stage drug candidates aimed at treating various conditions such as oncology, immunology, cardio-renal diseases, and infectious diseases. Everest Medicines aims to partner with innovative global companies to bring transformative pharmaceutical solutions to the Emerging Market, leveraging its expertise in clinical development, regulatory affairs, and business operations. The company's pipeline features several notable candidates, including Nefecon, EVER001, PTX-COVID19-B, and Eravacycline, among others.

Jianke is anonline B2C pharmacy and healthcare services platform.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

Iteos Therapeutics S.A. is a biotechnology company focused on developing immuno-oncology therapeutics to treat cancer patients. Headquartered in Gosselies, Belgium, the company was established in 2011 and operates as a subsidiary of Iteos Therapeutics, Inc. Its product pipeline features EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing open-label Phase 1/2a clinical trials in adult patients. Another key candidate is EOS-448, an anti-TIGIT antibody, also in Phase 1/2a clinical trials. Iteos Therapeutics aims to address immune suppression in the tumor microenvironment by creating small molecule immunomodulators, thereby enhancing the effectiveness of existing cancer treatments and newer immunomodulatory therapies. The company leverages expertise from the Ludwig Cancer Research Institute in its efforts to advance cancer therapies.